NASDAQ:TSHA

Taysha Gene Therapies Competitors

$24.53
-0.38 (-1.53 %)
(As of 04/16/2021 10:59 AM ET)
Add
Compare
Today's Range
$24.43
Now: $24.53
$25.18
50-Day Range
$19.29
MA: $23.81
$29.36
52-Week Range
$18.16
Now: $24.53
$33.35
Volume432 shs
Average Volume91,715 shs
Market Capitalization$926.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Taysha Gene Therapies (NASDAQ:TSHA) Vs. SWTX, NSTG, RLAY, RVMD, EDIT, and VCEL

Should you be buying TSHA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Taysha Gene Therapies, including SpringWorks Therapeutics (SWTX), NanoString Technologies (NSTG), Relay Therapeutics (RLAY), Revolution Medicines (RVMD), Editas Medicine (EDIT), and Vericel (VCEL).

Taysha Gene Therapies (NASDAQ:TSHA) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Institutional & Insider Ownership

42.2% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Taysha Gene Therapies and SpringWorks Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taysha Gene Therapies00603.00
SpringWorks Therapeutics00403.00

Taysha Gene Therapies currently has a consensus price target of $43.9167, indicating a potential upside of 79.03%. SpringWorks Therapeutics has a consensus price target of $95.20, indicating a potential upside of 33.26%. Given Taysha Gene Therapies' higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than SpringWorks Therapeutics.

Profitability

This table compares Taysha Gene Therapies and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taysha Gene TherapiesN/AN/AN/A
SpringWorks TherapeuticsN/A-24.48%-23.58%

Earnings and Valuation

This table compares Taysha Gene Therapies and SpringWorks Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taysha Gene TherapiesN/AN/AN/AN/AN/A
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-20.12

Summary

Taysha Gene Therapies beats SpringWorks Therapeutics on 4 of the 6 factors compared between the two stocks.

Taysha Gene Therapies (NASDAQ:TSHA) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Institutional & Insider Ownership

42.2% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are owned by institutional investors. 4.2% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Taysha Gene Therapies and NanoString Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taysha Gene Therapies00603.00
NanoString Technologies01402.80

Taysha Gene Therapies currently has a consensus price target of $43.9167, indicating a potential upside of 79.03%. NanoString Technologies has a consensus price target of $68.60, indicating a potential downside of 4.55%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than NanoString Technologies.

Profitability

This table compares Taysha Gene Therapies and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taysha Gene TherapiesN/AN/AN/A
NanoString Technologies-53.47%-68.96%-24.15%

Earnings and Valuation

This table compares Taysha Gene Therapies and NanoString Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taysha Gene TherapiesN/AN/AN/AN/AN/A
NanoString Technologies$125.57 million25.52$-40,700,000.00($1.93)-37.24

Taysha Gene Therapies has higher earnings, but lower revenue than NanoString Technologies.

Summary

Taysha Gene Therapies beats NanoString Technologies on 6 of the 9 factors compared between the two stocks.

Taysha Gene Therapies (NASDAQ:TSHA) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Profitability

This table compares Taysha Gene Therapies and Relay Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taysha Gene TherapiesN/AN/AN/A
Relay TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for Taysha Gene Therapies and Relay Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taysha Gene Therapies00603.00
Relay Therapeutics01502.83

Taysha Gene Therapies currently has a consensus price target of $43.9167, indicating a potential upside of 79.03%. Relay Therapeutics has a consensus price target of $57.40, indicating a potential upside of 77.22%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Relay Therapeutics.

Institutional & Insider Ownership

42.2% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Taysha Gene Therapies and Relay Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taysha Gene TherapiesN/AN/AN/AN/AN/A
Relay TherapeuticsN/AN/AN/AN/AN/A

Summary

Taysha Gene Therapies beats Relay Therapeutics on 3 of the 4 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Revolution Medicines and Taysha Gene Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
Taysha Gene TherapiesN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Revolution Medicines and Taysha Gene Therapies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines00203.00
Taysha Gene Therapies00603.00

Revolution Medicines currently has a consensus target price of $51.00, indicating a potential upside of 29.41%. Taysha Gene Therapies has a consensus target price of $43.9167, indicating a potential upside of 79.03%. Given Taysha Gene Therapies' higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Revolution Medicines.

Institutional & Insider Ownership

85.8% of Revolution Medicines shares are held by institutional investors. Comparatively, 42.2% of Taysha Gene Therapies shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Revolution Medicines and Taysha Gene Therapies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million57.79$-47,660,000.00N/AN/A
Taysha Gene TherapiesN/AN/AN/AN/AN/A

Taysha Gene Therapies has lower revenue, but higher earnings than Revolution Medicines.

Summary

Taysha Gene Therapies beats Revolution Medicines on 5 of the 7 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Editas Medicine and Taysha Gene Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Editas Medicine-99.62%-26.74%-16.38%
Taysha Gene TherapiesN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Editas Medicine and Taysha Gene Therapies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Editas Medicine44402.00
Taysha Gene Therapies00603.00

Editas Medicine currently has a consensus target price of $47.3636, indicating a potential upside of 33.98%. Taysha Gene Therapies has a consensus target price of $43.9167, indicating a potential upside of 79.03%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Editas Medicine.

Institutional & Insider Ownership

87.5% of Editas Medicine shares are held by institutional investors. Comparatively, 42.2% of Taysha Gene Therapies shares are held by institutional investors. 0.9% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Editas Medicine and Taysha Gene Therapies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$20.53 million115.99$-133,750,000.00($2.68)-13.19
Taysha Gene TherapiesN/AN/AN/AN/AN/A

Taysha Gene Therapies has lower revenue, but higher earnings than Editas Medicine.

Summary

Taysha Gene Therapies beats Editas Medicine on 6 of the 9 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Valuation & Earnings

This table compares Vericel and Taysha Gene Therapies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$117.85 million22.55$-9,660,000.00$0.18320.28
Taysha Gene TherapiesN/AN/AN/AN/AN/A

Taysha Gene Therapies has lower revenue, but higher earnings than Vericel.

Profitability

This table compares Vericel and Taysha Gene Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vericel0.12%0.13%0.10%
Taysha Gene TherapiesN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Vericel and Taysha Gene Therapies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vericel02602.75
Taysha Gene Therapies00603.00

Vericel currently has a consensus target price of $49.00, indicating a potential downside of 15.00%. Taysha Gene Therapies has a consensus target price of $43.9167, indicating a potential upside of 79.03%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Vericel.

Institutional & Insider Ownership

93.1% of Vericel shares are held by institutional investors. Comparatively, 42.2% of Taysha Gene Therapies shares are held by institutional investors. 4.3% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Vericel beats Taysha Gene Therapies on 6 of the 8 factors compared between the two stocks.


Taysha Gene Therapies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$71.44-3.0%$3.60 billionN/A-41.06Insider Selling
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$71.87-3.2%$3.31 billion$125.57 million-42.03Insider Selling
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.39-4.1%$3.05 billionN/A0.00News Coverage
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$39.41-0.8%$2.87 billion$50.04 million0.00
Editas Medicine logo
EDIT
Editas Medicine
1.6$35.35-15.9%$2.76 billion$20.53 million-20.32Analyst Report
Gap Up
Vericel logo
VCEL
Vericel
1.1$57.65-0.6%$2.67 billion$117.85 million-5,765,000.00Increase in Short Interest
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.36-1.1%$2.09 billion$31.43 million-5.04Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.16-1.6%$2.01 billion$48.83 million-14.68Analyst Report
bluebird bio logo
BLUE
bluebird bio
1.8$28.94-2.7%$2.00 billion$44.67 million-2.64
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.85-0.8%$1.95 billionN/A-11.14Decrease in Short Interest
Gap Up
NantKwest logo
NK
NantKwest
1.1$17.26-4.7%$1.89 billion$40,000.00-24.31
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.50-0.2%$1.73 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$76.36-0.3%$1.70 billionN/A-51.59
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.39-3.3%$1.69 billion$102.43 million-18.98
Immunovant logo
IMVT
Immunovant
1.8$15.58-1.9%$1.56 billionN/A-12.08Increase in Short Interest
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.38-4.3%$1.52 billion$35.23 million-13.86Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$18.93-4.0%$1.48 billion$7.80 million-17.69
AlloVir logo
ALVR
AlloVir
1.4$22.18-1.9%$1.47 billionN/A0.00Increase in Short Interest
Alector logo
ALEC
Alector
1.3$18.48-4.9%$1.47 billion$21.22 million-8.29
Replimune Group logo
REPL
Replimune Group
1.5$30.23-2.8%$1.45 billionN/A-17.08
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.08-2.6%$1.42 billionN/A0.00Increase in Short Interest
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$26.55-6.7%$1.34 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.89-1.2%$1.17 billion$32.16 million-10.10Analyst Upgrade
Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.24-5.3%$1.17 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.89-4.4%$1.16 billionN/A-3.98Increase in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$39.50-2.1%$1.14 billionN/A-16.46Analyst Downgrade
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.78-0.4%$1.06 billion$20.49 million-12.77Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.34-0.7%$1.04 billion$356.07 million7.03
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.41-5.9%$1.00 billionN/A0.00Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.00-6.8%$979.79 million$42.74 million-222.22Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
Passage Bio logo
PASG
Passage Bio
1.8$16.16-6.4%$925.89 millionN/A0.00Increase in Short Interest
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.77-7.2%$919.28 million$250,000.00-6.91Analyst Upgrade
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.01-0.8%$911.40 millionN/A-4.13Insider Selling
Increase in Short Interest
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.17-1.9%$904.23 millionN/A-9.99Increase in Short Interest
Analyst Revision
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.71-2.7%$850.59 millionN/A0.00Lockup Expiration
Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.68-1.4%$840.75 million$69.89 million-4.22
Cellectis logo
CLLS
Cellectis
1.3$19.13-0.9%$825.65 million$22.99 million-10.18
Inhibrx logo
INBX
Inhibrx
1.6$19.89-5.5%$791.95 millionN/A0.00Decrease in Short Interest
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.15-3.1%$784.23 million$2.51 million-3.73
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.89-3.1%$783.55 million$1.12 million-4.94Increase in Short Interest
Gap Up
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.11-2.3%$686.71 million$14.75 million-2.62Increase in Short Interest
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$19.90-1.8%$656.65 million$5.78 million-9.34Insider Selling
Unusual Options Activity
Analyst Revision
Vaxart logo
VXRT
Vaxart
1.3$5.23-3.8%$638.89 million$9.86 million-8.86
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.36-0.3%$633.42 million$13.29 million-10.18
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$28.12-8.9%$628.01 millionN/A0.00Lockup Expiration
Gap Down
Athira Pharma logo
ATHA
Athira Pharma
2.1$16.63-1.1%$610.62 millionN/A0.00Analyst Downgrade
Compugen logo
CGEN
Compugen
1.4$8.46-5.2%$608.94 million$17.80 million-22.86Analyst Report
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.73-3.0%$553.18 millionN/A-5.97Gap Up
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.62-3.2%$552.76 millionN/A-1.26Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.